Trials / Unknown
UnknownNCT04767087
Honey and Nigella Sativa in COVID-19 Prophylaxis
Honey and Nigella Sativa in the Prophylaxis of COVID-19: A Randomized Controlled Trial
- Status
- Unknown
- Phase
- Phase 2 / Phase 3
- Study type
- Interventional
- Enrollment
- 1,000 (estimated)
- Sponsor
- Sohaib Ashraf · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Accepted
Summary
Honey and Nigella sativa has established antiviral, antibacterial, anti-inflammatory, and immunomodulatory roles. So it is planned to test for its prophylaxis
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Honey | 0.5 gm/Kg/day honey |
| DRUG | Nigella sativa seed | 40 mg/Kg/day |
| OTHER | Placebo | empty capsule with sugar water |
Timeline
- Start date
- 2021-03-05
- Primary completion
- 2022-02-15
- Completion
- 2022-04-15
- First posted
- 2021-02-23
- Last updated
- 2021-07-02
Locations
1 site across 1 country: Pakistan
Source: ClinicalTrials.gov record NCT04767087. Inclusion in this directory is not an endorsement.